Cite
MOESM1 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â months
MLA
Riccio, Anna, et al. MOESM1 of Galectin-3: An Early Predictive Biomarker of Modulation of Airway Remodeling in Patients with Severe Asthma Treated with Omalizumab for 36Â Months. Jan. 2017. EBSCOhost, https://doi.org/10.6084/m9.figshare.c.3713917_d1.
APA
Riccio, A., Mauri, P., Ferrari, L., Rossi, R., Silvestre, D. D., Benazzi, L., Chiappori, A., Negro, R. D., Micheletto, C., & Canonica, G. (2017). MOESM1 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â months. https://doi.org/10.6084/m9.figshare.c.3713917_d1
Chicago
Riccio, Anna, Pierluigi Mauri, Laura Ferrari, Rossana Rossi, Dario Di Silvestre, Louise Benazzi, Alessandra Chiappori, Roberto Dal Negro, Claudio Micheletto, and Giorgio Canonica. 2017. “MOESM1 of Galectin-3: An Early Predictive Biomarker of Modulation of Airway Remodeling in Patients with Severe Asthma Treated with Omalizumab for 36Â Months,” January. doi:10.6084/m9.figshare.c.3713917_d1.